CR9623A - Anticuerpos humanizados especificos para nogo-a y sus usos farmaceuticos - Google Patents
Anticuerpos humanizados especificos para nogo-a y sus usos farmaceuticosInfo
- Publication number
- CR9623A CR9623A CR9623A CR9623A CR9623A CR 9623 A CR9623 A CR 9623A CR 9623 A CR9623 A CR 9623A CR 9623 A CR9623 A CR 9623A CR 9623 A CR9623 A CR 9623A
- Authority
- CR
- Costa Rica
- Prior art keywords
- nogo
- humanized antibodies
- pharmaceutical uses
- specific humanized
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invencion se refiere a anticuerpos para NOGO, a las formulaciones farmaceuticas que los contienen y al uso de tales anticuerpos en el tratamiento y/o profilaxis de enfermedades/trastornos neurologicos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0513766A GB0513766D0 (en) | 2005-07-05 | 2005-07-05 | Immunoglobulins |
GB0525448A GB0525448D0 (en) | 2005-12-14 | 2005-12-14 | Immunoglobulins |
Publications (1)
Publication Number | Publication Date |
---|---|
CR9623A true CR9623A (es) | 2008-04-10 |
Family
ID=37604821
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR9623A CR9623A (es) | 2005-07-05 | 2007-12-20 | Anticuerpos humanizados especificos para nogo-a y sus usos farmaceuticos |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP1899377B1 (es) |
JP (1) | JP2009500363A (es) |
KR (1) | KR20080030960A (es) |
AU (1) | AU2006265276B2 (es) |
BR (1) | BRPI0612734A2 (es) |
CA (1) | CA2614076A1 (es) |
CR (1) | CR9623A (es) |
CY (1) | CY1113310T1 (es) |
DK (1) | DK1899377T3 (es) |
EA (1) | EA014291B1 (es) |
ES (1) | ES2391902T3 (es) |
HK (1) | HK1115598A1 (es) |
HR (1) | HRP20120851T1 (es) |
IL (1) | IL188282A (es) |
MA (1) | MA29625B1 (es) |
NO (1) | NO20076663L (es) |
NZ (1) | NZ564567A (es) |
PL (1) | PL1899377T3 (es) |
PT (1) | PT1899377E (es) |
SG (1) | SG162829A1 (es) |
SI (1) | SI1899377T1 (es) |
WO (1) | WO2007003421A2 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1874821T3 (da) | 2005-04-26 | 2013-07-08 | Trion Pharma Gmbh | Kombination af antistoffer med glykokortikoider til behandling af kræft |
SI2158315T1 (sl) | 2007-06-25 | 2016-05-31 | Esbatech, An Alcon Biomedical Research Unit Llc | Postopki za spreminjanje protiteles in spremenjena protitelesa z izboljšanimi funkcionalnimi lastnostmi |
RU2513697C2 (ru) * | 2007-11-02 | 2014-04-20 | Новартис Аг | Улучшенные молекулы, связывающиеся с nogo-а и их фармацевтическое применение |
US20110268729A1 (en) * | 2008-07-11 | 2011-11-03 | Bams Abila | Treatment of amyotrophic lateral sclerosis by nogo-a-antagonist |
GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
KR20210118085A (ko) | 2018-12-21 | 2021-09-29 | 키맵 리미티드 | 공통 경쇄를 갖는 FIXaxFX 이중특이적 항체 |
GB2590642B (en) * | 2019-12-20 | 2024-02-14 | Kymab Ltd | Improved lambda antibodies |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0228832D0 (en) * | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
GB0321997D0 (en) * | 2003-09-19 | 2003-10-22 | Novartis Ag | Organic compound |
BRPI0417959A (pt) * | 2003-12-22 | 2007-03-27 | Glaxo Group Ltd | anticorpo ou fragmento funcional deste, composição farmcêutica, método para tratamento ou profilaxia de acidente vascular cerebral e outras doenças/distúrbios neurológicos em um ser humano, uso de um anticorpo anti-nogo, e, métodos para inibir a neurodegeneração e/ou promover a recuperação funcional em um paciente humano, para promover o crescimento axonal, para produzir um anticorpo anti-nogo e para produzir uma composição farmacêutica intravenosamente administrável |
-
2006
- 2006-07-03 AU AU2006265276A patent/AU2006265276B2/en not_active Ceased
- 2006-07-03 JP JP2008519855A patent/JP2009500363A/ja not_active Ceased
- 2006-07-03 EA EA200702634A patent/EA014291B1/ru not_active IP Right Cessation
- 2006-07-03 DK DK06776123.9T patent/DK1899377T3/da active
- 2006-07-03 KR KR1020077031031A patent/KR20080030960A/ko not_active Application Discontinuation
- 2006-07-03 PT PT06776123T patent/PT1899377E/pt unknown
- 2006-07-03 CA CA002614076A patent/CA2614076A1/en not_active Abandoned
- 2006-07-03 ES ES06776123T patent/ES2391902T3/es active Active
- 2006-07-03 SI SI200631454T patent/SI1899377T1/sl unknown
- 2006-07-03 BR BRPI0612734-7A patent/BRPI0612734A2/pt not_active IP Right Cessation
- 2006-07-03 SG SG201004551-6A patent/SG162829A1/en unknown
- 2006-07-03 PL PL06776123T patent/PL1899377T3/pl unknown
- 2006-07-03 WO PCT/EP2006/006535 patent/WO2007003421A2/en active Application Filing
- 2006-07-03 NZ NZ564567A patent/NZ564567A/en not_active IP Right Cessation
- 2006-07-03 EP EP06776123A patent/EP1899377B1/en active Active
-
2007
- 2007-12-20 IL IL188282A patent/IL188282A/en not_active IP Right Cessation
- 2007-12-20 CR CR9623A patent/CR9623A/es not_active Application Discontinuation
- 2007-12-28 NO NO20076663A patent/NO20076663L/no not_active Application Discontinuation
-
2008
- 2008-01-09 MA MA30565A patent/MA29625B1/fr unknown
- 2008-05-15 HK HK08105409.6A patent/HK1115598A1/xx not_active IP Right Cessation
-
2012
- 2012-10-23 HR HRP20120851TT patent/HRP20120851T1/hr unknown
- 2012-11-05 CY CY20121101051T patent/CY1113310T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
PL1899377T3 (pl) | 2013-01-31 |
SI1899377T1 (sl) | 2012-12-31 |
ES2391902T3 (es) | 2012-11-30 |
EA200702634A1 (ru) | 2008-06-30 |
NZ564567A (en) | 2010-09-30 |
NO20076663L (no) | 2008-02-27 |
BRPI0612734A2 (pt) | 2010-11-30 |
PT1899377E (pt) | 2012-11-20 |
CA2614076A1 (en) | 2007-01-11 |
JP2009500363A (ja) | 2009-01-08 |
DK1899377T3 (da) | 2012-11-12 |
SG162829A1 (en) | 2010-07-29 |
AU2006265276A1 (en) | 2007-01-11 |
EP1899377A2 (en) | 2008-03-19 |
MA29625B1 (fr) | 2008-07-01 |
WO2007003421A3 (en) | 2007-04-12 |
HK1115598A1 (en) | 2008-12-05 |
EP1899377B1 (en) | 2012-08-22 |
AU2006265276B2 (en) | 2011-10-13 |
KR20080030960A (ko) | 2008-04-07 |
IL188282A0 (en) | 2008-04-13 |
IL188282A (en) | 2011-04-28 |
EA014291B1 (ru) | 2010-10-29 |
WO2007003421A2 (en) | 2007-01-11 |
CY1113310T1 (el) | 2016-04-13 |
HRP20120851T1 (hr) | 2012-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR048912A1 (es) | Inmunoglobulinas anti-nogo | |
AR057239A1 (es) | Inmunoglobulinas | |
CL2020000483A1 (es) | Nuevos usos de derivados de piperidinil–indol. | |
PA8632801A1 (es) | Derivados de tetrahidronaftiridina | |
PA8621901A1 (es) | Derivados de sulfonamida para el tratamiento de enfermedades | |
PA8772101A1 (es) | Imidazol-triazolopirimidinas sustituidas | |
NI200700010A (es) | Moduladores de los receptores de alfa 7 acetilcolina nicotinica y sus usos terapéuticos | |
HN2004000319A (es) | "{ 1,8}naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia" | |
PA8770101A1 (es) | Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso | |
CR9623A (es) | Anticuerpos humanizados especificos para nogo-a y sus usos farmaceuticos | |
CR8858A (es) | Derivados de sulfamato y sulfamida para el tratamiento de epilepsia y trastornos relacionados | |
ECSP11011067A (es) | Compuestos para el tratamiento de enfermedades y desórdenes oftalmológicos | |
UY31048A1 (es) | Nuevos compuestos de pirimidina y usos de los mismos | |
ECSP067021A (es) | Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar) | |
DOP2010000069A (es) | Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso | |
AR054786A1 (es) | (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1 | |
PA8660301A1 (es) | Pirazolo piridinas sustituidas, composiciones que las contienen, procedimiento de fabricacion y utilizacion | |
UY29818A1 (es) | Nuevos compuestos de azetidina, composiciones farmaceuticas que los contienen, procesos de preparacion y sus usos terapeuticos | |
PA8604201A1 (es) | Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades | |
PA8627001A1 (es) | Compuestos para el tratamiento de enfermedades | |
CR10497A (es) | Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38 | |
GT200600161A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos | |
UY31322A1 (es) | Amidas heterocíclicas y sus métodos de uso-975 | |
ECSP11010956A (es) | Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos | |
CO6382089A2 (es) | Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |